Kelly Barghausen

Kelly Barghausen, Ph.D. is Director, Regulatory Affairs at Priovant Therapeutics. She joined Priovant from Urovant, where she was Associate Director of Regulatory Affairs, making significant contributions to the EMPOWUR study and the submission and FDA approval of the original NDA for GEMTESA® (vibegron). Kelly started her career in Regulatory Affairs at Duke University and has a background in molecular genetics, oncology, and pre-clinical disease modeling. She holds a Ph.D. in Biomedical Sciences from Florida State University College of Medicine as well as a Regulatory Affairs Certification (RAC US).